Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus, a developer of controlled release versions of known protein therapeutics, other drugs and vaccines on behalf of its clients, has entered into a process development and manufacturing pact with a Danish pharmaceutical company.
Subscribe to our email newsletter
As per the terms of the agreement, OctoPlus will act as a process development and manufacturing partner for microsphere-based formulation for the Danish pharma firm.
OctoPlus is a provider of formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide.
OctoPlus’ Locteron is a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C.
The company licensed Locteron exclusively to Biolex in October 2008.
Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.